ArticleBriefings in bioinformatics2026
Dynamic perturbation analysis: a modular rewiring framework for decoding cancer stage progression and identifying therapeutic vulnerabilities.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Disease progression is driven not only by transcriptional alterations but also by dynamic reorganization of molecular interaction networks. However, most existing approaches focus on differential gene expression and fail to capture modular-level reorganization. Here, we present dynamic perturbation analysis (DPA), a modular rewiring framework that quantifies dynamic perturbations across disease stages using a novel metric termed the degree of perturbation. Using gastric cancer (GC) progression as a model system, DPA revealed that extensive modular rewiring persists despite limited stage-specific transcriptional changes after tumor initiation. DPA identified progression-associated perturbation programs characterized by extracellular matrix remodeling, oncogenic signaling activation, stemness acquisition, and late-stage microenvironmental adaptation. Perturbation analysis revealed two major disease-driving programs and prioritized previously unrecognized regulators, including protein tyrosine phosphatase non-receptor type 12 (PTPN12) and leucine rich repeat and Ig domain containing 1 (LINGO1), whose functional roles in GC progression were experimentally validated. Furthermore, modular rewiring-guided drug repurposing uncovered PJ-34 as a promising therapeutic candidate targeting late-stage disease-associated perturbations. Collectively, DPA provides a generalizable framework for decoding disease progression through dynamic modular rewiring, enabling the identification of driver programs, candidate regulators, and therapeutic vulnerabilities. This framework offers a scalable strategy for network-guided mechanistic discovery and therapeutic prioritization in complex diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.